33 research outputs found
Changes in antibiotic use in Dutch hospitals over a six-year period: 1997 to 2002
OBJECTIVE: To analyse trends in antibiotic use in Dutch hospitals over the
period 1997 to 2002. METHODS: Data on the use of antibiotics and hospital
resource indicators were obtained by distributing a questionnaire to all
Dutch hospital pharmacies. Antibiotic use was expressed as the number of
defined daily doses (DDD) per 100 patient-days and as DDD per 100
admissions. RESULTS: Between 1997 and 2002, the mean length of stay
decreased by 18%. The mean number of admissions remained almost constant.
Total antibiotic use significantly increased by 24%, from 47.2 in 1997 to
58.5 DDD per 100 patient-days in 2002 (p<0.01), whereas expressed as DDD
per admissions it remained constant. Antibiotic use varied greatly between
the hospitals. Moreover, the mean number of DDD per hospital of
amoxicillin with clavulanic acid, clarithromycin, cefazolin, clindamycin
and ciprofloxacin increased by 16, 38, 39, 50 and 52%, respectively. Total
antibiotic use was higher in university hospitals than in general
hospitals. CONCLUSIONS: Between 1997 and 2002, patients hospitalised in
the Netherlands did not receive more antibiotics but, since they remained
in the hospital for fewer days, the number of DDD per 100 patient-days
increased. For macrolides, lincosamides and fluoroquinolones increases in
both DDD per 100 patient-days and in DDD per 100 admissions were observed.
It is arguable whether these trends result in an increase in selection
pressure towards resistance in the hospitals. Continuous surveillance of
antibiotic use and resistance is warranted to maintain efficacy and safety
of antibiotic treatment
Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
Objectives We aimed to evaluate the effects of
methotrexate (MTX) comedication added to biological
disease-modifying antirheumatic drugs (bDMARD) on
disease activity measures in patients with rheumatoid
arthritis (RA) in routine care.
Methods Patients with RA on treatment with either
bDMARDs or conventional synthetic DMARDs were
included in this prospective cohort study. The effect of
(time-varying) combination therapy with bDMARD and
MTX compared with bDMARD monotherapy was tested
in longitudinal generalised estimating equation models
using as outcomes: (1) the likelihood to be in remission
according to the 28-joint Disease Activity Score (DAS28)
erythrocyte sedimentation rate (ESR) (<2.6) and to the
Routine Assessment of Patient Index Data 3 (RAPID3)
(0–30; ≤3), a patient-reported outcome measure about RA
symptoms; and (2) DAS28-ESR and RAPID3 as continuous
variables. All models were adjusted for potential
confounders: age, gender, drugs for comorbidities (yes/no),
oral steroids (yes/no) and non-steroidal anti-inflammatory
drug (yes/no).
Results In total, 330 patients were included (mean
(SD) follow-up; 10.7 (9.7) months). Compared with
bDMARD monotherapy, MTX combination therapy was
significantly associated with a 55% higher likelihood to be
in DAS28 remission, but not RAPID3 remission, over time.
Combination therapy resulted in slightly, but statistically
significant, lower levels of DAS28-ESR over time (β=−0.42
(95% CI −0.67 to − 0.17)), but not RAPID3 (β=−0.58 (95%
CI −0.65 to 0.49)). The effect on DAS28-ESR was entirely
explained by lower swollen joint counts and was persistent
after correction for confounders.
Conclusion These results give support to the policy that
MTX should be continued in routine care patients with RA
on biological therapy since this leads to better objective
but not subjective clinical outcome
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice
Objective To test the longitudinal association between patient-reported outcome, Routine Assessment of Patient Index Data 3 (RAPID3) and the Disease Activity Score in 28 joints that includes the erythrocyte sedimentation rate (DAS28-ESR) in routine-care patients with rheumatoid arthritis (RA). Methods Patients with RA treated with disease-modifying antirheumatic drugs were included in this prospective observational cohort. The longitudinal association between RAPID3 (0-10) and DAS28-ESR and its individual components (swollen joint count (SJC), erythrocyte sedimentation rate (ESR) (mm/hour), tender joint count (TJC) and patient global assessment (PGA)) was tested using generalised estimating equations in patients with more than two consecutive visits with data on RAPID3 and DAS28-ESR. Interactions between RAPID3 and gender, pain, PGA and age at baseline were tested, and if significant (p<0.20) and clinically relevant, models were fit in the corresponding strata. Results In total, 330 patients were included (mean follow-up 10.7 (SD 9.7) months, female gender 67.9%). The longitudinal association between RAPID3 and DAS28-ESR was weak (\xce\xb2=0.29 (95% CI 0.24 to 0.35), n=207), meaning that one unit increase in RAPID3 corresponded to a 0.29 unit increase in Disease Activity Score in 28 joints (DAS28). RAPID3 was most strongly associated with subjective (TJC: \xce\xb2=0.89 (95% CI 0.61 to 1.17); PGA: \xce\xb2=0.94 (95% CI 0.84 to 1.04)) and not with objective components of DAS28 (SJC: \xce\xb2=0.29 (95% CI 0.17 to 0.41), n=172). The association between RAPID3 and ESR was poor but modified by gender, being only significant in men (\xce\xb2=0.37 (95% CI 0.08 to 0.67)). Conclusions These data suggest that RAPID3 does not sufficiently capture changes in objective inflammatory signs. Monitoring by RAPID3 alone is therefore insufficient to follow disease activity in patients wth RA in clinical practice
A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: Study Protocol
<p>Abstract</p> <p>Background</p> <p>The use of guidelines in general practice is not optimal. Although evidence-based methods to improve guideline adherence are available, variation in physician adherence to general practice guidelines remains relatively high. The objective for this study is to transfer a quality improvement strategy based on audit, feedback, educational materials, and peer group discussion moderated by local opinion leaders to the field. The research questions are: is the multifaceted strategy implemented on a large scale as planned?; what is the effect on general practitioners' (GPs) test ordering and prescribing behaviour?; and what are the costs of implementing the strategy?</p> <p>Methods</p> <p>In order to evaluate the effects, costs and feasibility of this new strategy we plan a multi-centre cluster randomized controlled trial (RCT) with a balanced incomplete block design. Local GP groups in the south of the Netherlands already taking part in pharmacotherapeutic audit meeting groups, will be recruited by regional health officers. Approximately 50 groups of GPs will be randomly allocated to two arms. These GPs will be offered two different balanced sets of clinical topics. Each GP within a group will receive comparative feedback on test ordering and prescribing performance. The feedback will be discussed in the group and working agreements will be created after discussion of the guidelines and barriers to change. The data for the feedback will be collected from existing and newly formed databases, both at baseline and after one year.</p> <p>Discussion</p> <p>We are not aware of published studies on successes and failures of attempts to transfer to the stakeholders in the field a multifaceted strategy aimed at GPs' test ordering and prescribing behaviour. This pragmatic study will focus on compatibility with existing infrastructure, while permitting a certain degree of adaptation to local needs and routines.</p> <p>Trial registration</p> <p>Nederlands Trial Register ISRCTN40008171</p
The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports
InforMatrix for attention deficit hyperactivity disorder
The purpose of this review is to facilitate discussion on drug selection for the treatment of ADHD by using only clinically relevant selection criteria and providing an up-to-date overview. The InforMatrix method was used to select drugs to treat attention deficit hyperactivity disorder (ADHD). The following selection criteria were applied: clinical efficacy, safety, tolerability, ease of use, applicability, and cost. The drugs approved for ADHD in the Netherlands were included in the analysis, namely: atomoxetine, immediate-release methylphenidate, and various formulations of slow-release methylphenidate (Concerta, Equasym and Medikinet). Most studies are of limited quality, duration, and size. In one study, Concerta was more effective than atomoxetine. Although no relevant differences were seen in other comparative studies, the clinical experience with atomoxetine is still limited and unexpected toxicity cannot be excluded; few studies have been published with Equasym and Medikinet. No major differences were seen in general tolerability between the drugs. The ease of use of immediate-release methylphenidate is less than for the other drugs. The acquisition cost of immediate-release methylphenidate is considerably lower than that of the slow-release formulations. Atomoxetine is the most expensive drug. The InforMatrix program is available in an interactive format. It enables the user to judge both the importance of the selection criteria and the properties of each therapeutic option per criterion on the basis of his or her own personal expertise and/or the present document